메뉴 건너뛰기




Volumn 22, Issue 1, 2008, Pages 7-16

Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: The CARe study

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

EID: 38149023571     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.0013     Document Type: Article
Times cited : (11)

References (28)
  • 1
    • 0032447719 scopus 로고    scopus 로고
    • Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy
    • Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther 1998;3:215-220.
    • (1998) Antivir Ther , vol.3 , pp. 215-220
    • Burger, D.M.1    Hoetelmans, R.M.2    Hugen, P.W.3
  • 2
    • 0035824741 scopus 로고    scopus 로고
    • Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals
    • Phillips AN, Miller V, Sabin C, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS 2001;15:2379-2384.
    • (2001) AIDS , vol.15 , pp. 2379-2384
    • Phillips, A.N.1    Miller, V.2    Sabin, C.3
  • 3
    • 0034319263 scopus 로고    scopus 로고
    • Prospective randomized two arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy
    • Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;25:221-228.
    • (2000) J Acquir Immune Defic Syndr , vol.25 , pp. 221-228
    • Tuldra, A.1    Fumaz, C.R.2    Ferrer, M.J.3
  • 4
    • 0035902939 scopus 로고    scopus 로고
    • Simplification with abacavir based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA
    • Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-1526.
    • (2001) AIDS , vol.15 , pp. 1517-1526
    • Clumeck, N.1    Goebel, F.2    Rozenbaum, W.3
  • 5
    • 0035876184 scopus 로고    scopus 로고
    • High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals
    • Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001;15:1089-1095.
    • (2001) AIDS , vol.15 , pp. 1089-1095
    • Veldkamp, A.I.1    Weverling, G.J.2    Lange, J.M.3
  • 6
    • 0035198762 scopus 로고    scopus 로고
    • Principles and practice of HIV-protease inhibitor pharmacoenhancement
    • Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001;2:105-113.
    • (2001) HIV Med , vol.2 , pp. 105-113
    • Moyle, G.J.1    Back, D.2
  • 7
    • 0033972441 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
    • Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
    • (2000) Clin Pharmacokinet , vol.38 , pp. 41-57
    • Dresser, G.K.1    Spence, J.D.2    Bailey, D.G.3
  • 8
    • 0035461510 scopus 로고    scopus 로고
    • Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration
    • Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 2001;52:255-264.
    • (2001) Br J Clin Pharmacol , vol.52 , pp. 255-264
    • Buss, N.1    Snell, P.2    Bock, J.3    Hsu, A.4    Jorga, K.5
  • 9
    • 0035477744 scopus 로고    scopus 로고
    • Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: Survey of women in the HERS study
    • Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the HERS study. J Acquir Immune Defic Syndr 2001;28:124-131.
    • (2001) J Acquir Immune Defic Syndr , vol.28 , pp. 124-131
    • Stone, V.E.1    Hogan, J.W.2    Schuman, P.3
  • 10
    • 0035958773 scopus 로고    scopus 로고
    • Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults
    • Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS 2001;15:1369-1377.
    • (2001) AIDS , vol.15 , pp. 1369-1377
    • Bartlett, J.A.1    DeMasi, R.2    Quinn, J.3    Moxham, C.4    Rousseau, F.5
  • 11
    • 0038078754 scopus 로고    scopus 로고
    • Reviving protease inhibitors: New data and more options
    • Murphy RL. Reviving protease inhibitors: new data and more options. J Acquir Immune Defic Syndr 2003;33:S43-52.
    • (2003) J Acquir Immune Defic Syndr , vol.33
    • Murphy, R.L.1
  • 12
    • 0347128503 scopus 로고    scopus 로고
    • Lipid abnormalities during ART: It's the drug, not the class
    • Moyle GJ. Lipid abnormalities during ART: It's the drug, not the class. AIDS Read 2004;14:15-22.
    • (2004) AIDS Read , vol.14 , pp. 15-22
    • Moyle, G.J.1
  • 13
    • 0041733063 scopus 로고    scopus 로고
    • Goldsmith DR, Perry CM. Atazanavir. Drugs 2003;63:1679-1693; discussion 1694-1695.
    • Goldsmith DR, Perry CM. Atazanavir. Drugs 2003;63:1679-1693; discussion 1694-1695.
  • 14
    • 2942527107 scopus 로고    scopus 로고
    • Atazanavir: New option for treatment of HIV infection
    • Havlir DV, O'Marro SD. Atazanavir: New option for treatment of HIV infection. Clin Infect Dis 2004;38:1599-1604.
    • (2004) Clin Infect Dis , vol.38 , pp. 1599-1604
    • Havlir, D.V.1    O'Marro, S.D.2
  • 15
    • 3342924014 scopus 로고    scopus 로고
    • Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV
    • Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36:1011-1019.
    • (2004) J Acquir Immune Defic Syndr , vol.36 , pp. 1011-1019
    • Squires, K.1    Lazzarin, A.2    Gatell, J.M.3
  • 16
    • 0037234238 scopus 로고    scopus 로고
    • Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects
    • Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003;32:18-29.
    • (2003) J Acquir Immune Defic Syndr , vol.32 , pp. 18-29
    • Sanne, I.1    Piliero, P.2    Squires, K.3    Thiry, A.4    Schnittman, S.5
  • 17
    • 1642465026 scopus 로고    scopus 로고
    • Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results
    • Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003;17:2603-2614.
    • (2003) AIDS , vol.17 , pp. 2603-2614
    • Murphy, R.L.1    Sanne, I.2    Cahn, P.3
  • 18
    • 2542489421 scopus 로고    scopus 로고
    • Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir
    • Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004;36:684-692.
    • (2004) J Acquir Immune Defic Syndr , vol.36 , pp. 684-692
    • Wood, R.1    Phanuphak, P.2    Cahn, P.3
  • 19
    • 33747126527 scopus 로고    scopus 로고
    • Efficacy and safety of atazanavir (ATV)-based HAART in patients switched from a stable boosted or unboosted protease inhibitor (PI) treatment. The SWAN Study: Final Results (48 Weeks)
    • Dublin: November
    • Gatell JM, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir (ATV)-based HAART in patients switched from a stable boosted or unboosted protease inhibitor (PI) treatment. The SWAN Study: Final Results (48 Weeks). 10th European AIDS Conference. Dublin: November 2005.
    • (2005) 10th European AIDS Conference
    • Gatell, J.M.1    Salmon-Ceron, D.2    Lazzarin, A.3
  • 20
    • 70349451266 scopus 로고    scopus 로고
    • Open-label, pilot trial of regimen simplification to atazanavir/ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression (ACTG 5201)
    • Denver: February
    • Swindells S, Wilkin T, DiRienzo G, et al. Open-label, pilot trial of regimen simplification to atazanavir/ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression (ACTG 5201). 13th Conference on Retroviruses and Opportunistic Infections. Denver: February 2006.
    • (2006) 13th Conference on Retroviruses and Opportunistic Infections
    • Swindells, S.1    Wilkin, T.2    DiRienzo, G.3
  • 21
    • 33747141841 scopus 로고    scopus 로고
    • Efficacy and safety of atazanavir-based therapy in antiretroviral naïve HIV-1 infected subjects, both with and without ritonavir: 48 week results from AI424-089
    • abstract 107LB, Denver: February
    • Malan N, Krantz E, David N, et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naïve HIV-1 infected subjects, both with and without ritonavir: 48 week results from AI424-089 [abstract 107LB]. 13th Conference on Retroviruses and Opportunistic Infections. Denver: February 2006.
    • (2006) 13th Conference on Retroviruses and Opportunistic Infections
    • Malan, N.1    Krantz, E.2    David, N.3
  • 22
    • 27144482749 scopus 로고    scopus 로고
    • Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: A randomized multinational trial
    • Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: A randomized multinational trial. Curr Med Res Opin 2005;21:1683-1692.
    • (2005) Curr Med Res Opin , vol.21 , pp. 1683-1692
    • Cohen, C.1    Nieto-Cisneros, L.2    Zala, C.3
  • 23
    • 17844387166 scopus 로고    scopus 로고
    • Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
    • Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-694.
    • (2005) AIDS , vol.19 , pp. 685-694
    • Johnson, M.1    Grinsztejn, B.2    Rodriguez, C.3
  • 24
    • 33646744190 scopus 로고    scopus 로고
    • 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
    • Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-718.
    • (2006) AIDS , vol.20 , pp. 711-718
    • Johnson, M.1    Grinsztejn, B.2    Rodriguez, C.3
  • 25
    • 33750999624 scopus 로고    scopus 로고
    • on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)
    • Gazzard B, on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006;7:487-503.
    • (2006) HIV Med , vol.7 , pp. 487-503
    • Gazzard, B.1
  • 27
    • 7944228403 scopus 로고    scopus 로고
    • Predictors of virological response to atazanavir in protease inhibitor-experienced patients
    • Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials 2004;5:201-205.
    • (2004) HIV Clin Trials , vol.5 , pp. 201-205
    • Barrios, A.1    Rendon, A.L.2    Gallego, O.3
  • 28
    • 33846460075 scopus 로고    scopus 로고
    • Different patterns of mutations involved in the genotypic resistance score for atazanavir boosted versus atazanavir unboosted in multiply failing patients [Abstract 89]. XV International HIV Drug Resistance Workshop. Sitges: June 2006
    • Bertoli A, Santoro MM, Lorenzini P, et al. Different patterns of mutations involved in the genotypic resistance score for atazanavir boosted versus atazanavir unboosted in multiply failing patients [Abstract 89]. XV International HIV Drug Resistance Workshop. Sitges: June 2006. Antivir Ther 2006;11:S99.
    • (2006) Antivir Ther , vol.11
    • Bertoli, A.1    Santoro, M.M.2    Lorenzini, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.